Zonghai Li

Zonghai Li

Professor,State Key Laboratory of Oncogenes and Related Genes,

Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine

Title：

Treatment of solid tumor with chimeric antigen receptor- engineered T cells: current status and future prospectives

Abstract：Chimeric antigen receptors (CAR) are artificial recombinant receptors that generally combine the antigen-recognition domain of a monoclonal antibody with the T cell activation domains. Recent years, great success has already been achieved in the clinical trials on CD19-specific CAR T cell therapy for B cell leukemia. Nevertheless, solid tumors remain to be a big challenge for CAR T therapy. In this review, the preclinical and clinical studies on the treatment of solid tumors with CAR-T cells will be summarized. The major hurdles for the success of CAR-T and novel strategies to address these hurdles will also be described and discussed.